logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 10 of 10 Items
Showing 1 - 10 of 10 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

Bonnet MMB, Bhatt NB, Baudin E, Silva C, Michon C,  et al.
2013-04-01 • Lancet Infectious Diseases
2013-04-01 • Lancet Infectious Diseases
BACKGROUND
In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antitube...
Journal Article
|
Research

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Sissoko D, Laouenan C, Folkesson E, M’Lebing A, Beavogui A,  et al.
2016-03-01 • PLOS Medicine
2016-03-01 • PLOS Medicine
Ebola virus disease (EVD) is a highly lethal condition for which no specific treatment has proven efficacy. In September 2014, while the Ebola outbreak was at its peak, the World Health ...
Journal Article
|
Pre-Print

Early assessment of antiretroviral efficacy is critical to prevent the emergence of resistance mutations in HIV-tuberculosis coinfected patients: a substudy of the CARINEMO-ANRS12146 trial

Baudin E, Bhatt NB, Rouzioux C, Serafini M, Molfino L,  et al.
2019-02-08 • F1000Research
2019-02-08 • F1000Research
BACKGROUND
In the CARINEMO ANRS 12146 clinical trial, HIV-tuberculosis co-infected patients in Mozambique were randomized to nevirapine (NVP) or to efavirenz (EFV)-based antiretrovir...
Journal Article
|
Research

Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment

Bhatt NB, Barau C, Amin A, Baudin E, Meggi B,  et al.
2014-03-24 • Antimicrobial Agents and Chemotherapy
2014-03-24 • Antimicrobial Agents and Chemotherapy
This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patien...
Journal Article
|
Research

Favipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower Than Targeted

Nguyen TN, Guedj J, Anglaret X, Laouenan C, Madelain V,  et al.
2017-02-23 • PLOS Neglected Tropical Diseases
2017-02-23 • PLOS Neglected Tropical Diseases
In 2014-2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for thi...
Journal Article
|
Research

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)

Borand L, Madec Y, Laureillard D, Chou M, Marcy O,  et al.
2014-03-07 • PLOS One
2014-03-07 • PLOS One
OBJECTIVE
To assess efavirenz plasma concentrations and their association with treatment efficacy and tolerance of efavirenz 600 mg daily in HIV-tuberculosis co-infected patients.
Journal Article
|
Research

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship

Bhatt NB, Baudin E, Meggi B, da Silva C, Barrail-Tran A,  et al.
2014-09-18 • Journal of Antimicrobial Chemotherapy
2014-09-18 • Journal of Antimicrobial Chemotherapy
OBJECTIVES
We describe nevirapine and efavirenz exposure on and off tuberculosis treatment and consequences for virological efficacy and tolerance in patients included in the ANRS 12...
Journal Article
|
Research

Positive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia

Ferradini LLF, Laureillard D, Prak N, Ngeth C, Fernandez MAL,  et al.
2007-11-12 • AIDS
2007-11-12 • AIDS
OBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunologica...
Journal Article
|
Review

Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review

Atwine D, Bonnet MMB, Taburet AM
2018-05-22 • British Journal of Clinical Pharmacology
2018-05-22 • British Journal of Clinical Pharmacology
AIMS
Efavirenz (EFV) and rifampicin-isoniazid (RH) are cornerstone drugs in human immunodeficiency virus (HIV)-tuberculosis (TB) coinfection treatment but with complex drug interacti...
Journal Article
|
Research

Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda

Ahoua L, Guenther G, Rouzioux C, Pinoges LLP, Anguzu P,  et al.
2011-07-26 • BMC Pediatrics
2011-07-26 • BMC Pediatrics
Children living with HIV continue to be in urgent need of combined antiretroviral therapy (ART). Strategies to scale up and improve pediatric HIV care in resource-poor regions, especiall...